Antiplatelet Therapy Bridging With Cangrelor in Patients With Coronary Stents: A Case Series.
Adenosine Monophosphate
/ administration & dosage
Administration, Oral
Aged
Aged, 80 and over
Coronary Thrombosis
/ complications
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Substitution
Female
Humans
Male
Middle Aged
Percutaneous Coronary Intervention
/ adverse effects
Platelet Aggregation Inhibitors
/ administration & dosage
Platelet Function Tests
Postoperative Care
/ methods
Postoperative Complications
/ prevention & control
Purinergic P2Y Receptor Antagonists
/ administration & dosage
Retrospective Studies
Stents
/ adverse effects
Treatment Outcome
acute coronary syndrome
antiplatelets
bare metal stent
cardiovascular drugs
coronary artery disease
drug eluting stent
ischemic heart disease
myocardial infarction
percutaneous coronary intervention
Journal
The Annals of pharmacotherapy
ISSN: 1542-6270
Titre abrégé: Ann Pharmacother
Pays: United States
ID NLM: 9203131
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
pubmed:
23
8
2018
medline:
6
2
2020
entrez:
23
8
2018
Statut:
ppublish
Résumé
Cangrelor is an intravenous P2Y To describe the dosing, laboratory monitoring, and clinical outcomes of a series of patients who received cangrelor as a "bridging" antiplatelet agent. This study is a retrospective analysis of all patients within the study center with coronary stents who received cangrelor as a bridge to surgical procedure and had VerifyNow monitoring during treatment. A total of 11 patients were identified for inclusion. The median cangrelor dose was 0.5 µg/kg/min (interquartile range = 0.5-0.5) and was maintained in 7 of 11 patients. Doses ranged from 0.25 to 2 µg/kg/min during therapy, and 81.6% of VerifyNow results assessed were within goal range (⩽208 P2Y
Sections du résumé
BACKGROUND
Cangrelor is an intravenous P2Y
OBJECTIVE
To describe the dosing, laboratory monitoring, and clinical outcomes of a series of patients who received cangrelor as a "bridging" antiplatelet agent.
METHODS
This study is a retrospective analysis of all patients within the study center with coronary stents who received cangrelor as a bridge to surgical procedure and had VerifyNow monitoring during treatment.
RESULTS
A total of 11 patients were identified for inclusion. The median cangrelor dose was 0.5 µg/kg/min (interquartile range = 0.5-0.5) and was maintained in 7 of 11 patients. Doses ranged from 0.25 to 2 µg/kg/min during therapy, and 81.6% of VerifyNow results assessed were within goal range (⩽208 P2Y
Identifiants
pubmed: 30132336
doi: 10.1177/1060028018795840
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Purinergic P2Y Receptor Antagonists
0
Adenosine Monophosphate
415SHH325A
cangrelor
6AQ1Y404U7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM